Results 91 to 100 of about 188,791 (289)
B cells in SLE. Different biological drugs for different pathogenic mechanisms [PDF]
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by a complex multi-factorial pathogenesis and a great clinical polymorphism. SLE is considered to be a B cell disease in which autoantibodies are the major players. Recently,
Carsetti, Rita +3 more
core +1 more source
Retractions in Rheumatology: Trends, Causes, and Implications for Research Integrity
Objective We aimed to describe the trends and main reasons for study retraction in rheumatology literature. Methods We reviewed the Retraction Watch database to identify retracted articles in rheumatology. We recorded the main study characteristics, authors’ countries, reasons for retraction, time from publication to retraction, and trends over time ...
Anna Maria Vettori, Michele Iudici
wiley +1 more source
A Case of Primary Biliary Cirrhosis That Progressed Rapidly after Treatment Involving Rituximab
Primary biliary cirrhosis (PBC) is a progressive liver disease for which limited therapies are recommended. Rituximab, an anti-CD20 monoclonal antibody, is expected to be a useful therapeutic regimen for PBC.
Kazuto Tajiri +5 more
doaj +1 more source
A Case of Statin-Associated Autoimmune Myopathy. [PDF]
A 70-year-old previously independent man developed progressive proximal leg weakness resulting in a fall at home suffering traumatic brain injury. He was prescribed a statin medication two years prior, but this was discontinued on admission to the ...
Dokukin, Andrei N +6 more
core +3 more sources
Objective Systemic lupus erythematosus (SLE) is a heterogenous inflammatory condition with widely varying global prevalence estimates. The frequency of SLE in the general population of Australia has been reported to be notably lower than contemporary estimates in countries such as the United States or United Kingdom, at 19 to 39 per 100,000 as opposed ...
Lucinda Roper +7 more
wiley +1 more source
Background The addition of rituximab (R) to CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) -like therapy has improved survival in primary mediastinal B-cell lymphoma (PMBCL) patients.
K. Lisenko +6 more
doaj +1 more source
Objective We aimed to construct and evaluate the first laboratory‐based frailty index (FI‐Lab) for predicting adverse outcomes in systemic lupus erythematosus (SLE) and to compare its predictive ability to that of an existing clinical FI. Methods We used data from a single‐center prospective cohort of adult patients with SLE whose baseline visit ...
Grace Burns +2 more
wiley +1 more source
Rituximab in childhood steroid-dependent nephrotic syndrome: a single-center experience
Background Most children with idiopathic nephrotic syndrome are steroid-sensitive. However, the majority of them relapse. Unfortunately, 50–70% of relapsers will develop frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome ...
Shrouq Badr +3 more
doaj +1 more source
A sore red eye with systemic involvement [PDF]
The study of happiness has long been a playground for philosophical speculation. By lack of empirical measures of happiness, it was not possible to check propositions about the matter.
Lightman, SL +3 more
core +1 more source
People with systemic autoimmune and rheumatic diseases (SARDs) are at higher risk than the general population of experiencing adverse pregnancy and perinatal outcomes such as preeclampsia, intrauterine growth restriction, and maternal and/or fetal death.
Mehret Birru Talabi, Sonya Borrero
wiley +1 more source

